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Previous studies have demonstrated increased tau plasma levels in patients with Alzheimer’s disease 
(AD) and mild cognitive impairment (MCI) due to AD. Much less is known whether increased tau 
plasma levels can already be detected in the pre-MCI stage of subjective cognitive decline (SCD). 
In the present study we measured tau plasma levels in 111 SCD patients and 134 age- and gender-
matched cognitively healthy controls participating in the DZNE (German Center for Neurodegenerative 
Diseases) longitudinal study on cognition and dementia (DELCODE). Tau plasma levels were measured 
using ultra-sensitive, single-molecule array (Simoa) technology. We found no significant different tau 
plasma levels in SCD (3.4 pg/ml) compared with healthy controls (3.6 pg/ml) after controlling for age, 
gender, and education (p = 0.137). In addition, tau plasma levels did not correlate with Aβ42 (r = 0.073; 
p = 0.634), tau (r = −0.179; p = 0.240), and p-tau181 (r = −0.208; p = 0.171) cerebrospinal fluid (CSF) 
levels in a subgroup of 45 SCD patients with available CSF. In conclusion, plasma tau is not increased in 
SCD patients. In addition, the lack of correlation between tau in plasma and CSF in the examined cohort 
suggests that tau levels are affected by different factors in both biofluids.
Brain deposition of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau is a hallmark of 
Alzheimer’s disease (AD) pathology1. Several tau tracers for positron emission tomography (PET) imaging 
including 18F-TH523 have been developed over the past few years2. As in the brain itself, tau levels in the cere-
brospinal fluid (CSF) were found to be increased in AD patients3. Therefore, CSF tau provides a useful marker of 
tau pathology. Several tau-based therapeutic approaches are currently investigated. Thus, detection of tau levels 
holds enormous potential for both early diagnosis of AD and monitoring of disease-modifying therapeutics.
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An ideal test for diagnosis and monitoring of disease-modifying therapeutics in AD should be applicable with 
the lowest possible risk, easy and fast to perform and cheap. A blood test would fulfil all of these conditions in 
contrast to PET neuroimaging (expensive; exposure to ionizing radiation) and CSF analysis (invasive). Indeed, 
several previous studies have demonstrated increased tau plasma levels in patients with AD4–6, in a group of 
patients with AD and mild cognitive impairment (MCI) due to AD7 and in MCI due to AD4. Much less is known 
whether increased tau plasma levels can already be detected in the pre-MCI stage of subjective cognitive decline 
(SCD). Only one recent study examined this association and failed to demonstrate increased tau plasma levels in 
SCD patients5.
SCD is actually considered to be associated with an increased likelihood of future cognitive impairment and 
dementia, especially in those cases with worry about memory8–10. According to the suggestions made by the 
Working Group of the Subjective Cognitive Decline Initiative (SCD-I)11, SCD is defined as personal complaints 
about ones’ cognitive state in the absence of objective cognitive impairment. This definition of SCD was also used 
in the present study.
The aim of the present study was to examine tau plasma levels in SCD patients and healthy controls (HC) 
participating in the DELCODE study and to investigate the association with clinical parameters (age, gender, and 
education), neuropsychological parameters (Mini-Mental-State Examination [MMSE], Clinical Dementia Rating 
[CDR], and logical memory subtest of the Wechsler Memory Scale) and biochemical markers of AD (CSF levels 
of beta-amyloid 42 [Aβ42], tau and phosphorylated tau181 [p-tau181]).
Materials and Methods
Subjects. 111 SCD patients and 134 age- and gender-matched cognitively healthy controls were included in 
the study (Table 1). These participants were recruited from the DELCODE study. DELCODE is an observational 
longitudinal memory clinic-based multicenter study in Germany. The aim of this still ongoing study is to enroll 
subjects with SCD, MCI patients, AD dementia patients, control subjects without subjective or objective cognitive 
decline and first degree relatives of patients with a documented diagnosis of AD dementia.
All participants underwent MMSE-scoring12, clinical assessment of cognitive status by means of the CDR 
scale13, 14, and the logical memory subtest of the Wechsler Memory Scale (i.e. immediate [LogMem I] and delayed 
story recall [LogMem II].
SCD was defined if participants were cognitively unimpaired and stated to have decline in cognitive function-
ing unrelated to an event or condition explaining the cognitive deficits according to recent research criteria11.
HC individuals never reported SCD and had no history of neurological or psychiatric disease or any sign of 
cognitive decline. Aβ42, tau and p-tau181 CSF levels were measured in the central lab of the DZNE in Bonn. 
Cut-offs for normal and abnormal concentrations of Aß42 (<600 pg/ml) and of the ratio Aß42/Aß40 (<0.09) 
were derived from the literature, which applied the respective assays15. For tau (>470 pg/ml) and p-tau181 (57 pg/
ml) we used cut-offs established locally (Bonn) based on clinical and non-impaired control samples. In addition, 
we defined an abnormal Aβ42/tau ratio according to the formula of Hulstaert16 (Aβ42/[240 + 1.18 × tau] < 1), 
which has been shown to be a useful indicator of AD pathology17.
Experimental protocols described in the present study have been approved by the Ethik-Kommission an 
der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen. All other 
aspects of the study have been approved by the institutional review boards for each of the participating sites in the 
DELCODE study. All methods were performed in accordance with the relevant guidelines and regulations. All 
participants provided written, informed consent.
Blood sampling. Blood was obtained in the morning (9.00–10.00 A.M.; in the fasting state). Venous blood 
was collected in EDTA plasma tubes. EDTA plasma samples were centrifuged for 15 minutes at 10.000 g within 
30 minutes of collection. Samples were aliquoted and stored at −80 °C before analysis.
Simoa analysis. Plasma tau levels were determined using ultra-sensitive, single-molecule array (Simoa) 
technology18. Measurements were performed at the Natural and Medical Sciences Institute using the Human 
HC SMC p-value
N 134 111
Age (y) 68.5 (5.0) 71.3 (5.6) <0.001
Gender (m/f) 80/54 60/51 0.374
Education (y) 14. 9 (2.7) 14.7 (3.1) 0.450
MMSE 29.5 (0.9) 29.2 (1.0) 0.285
CDR 0.0 (0.0) 0.2 (0.2) <0.001
LogMem I 15.1 (3.6) 14.6 (3.8) 0.960
LogMem II 13.9 (3.6) 13.1 (3.9) 0.585
Plasma tau 3.6 (1.7) 3.4 (1.2) 0.137
Table 1. Clinical and demographic characteristics of HC individuals and SCD patients. Note: Values are 
expressed as mean (standard deviation). N: number; HC: healthy control individuals; SCD: patients with 
subjective cognitive decline; m/f: male/female; MMSE: Mini Mental State Examination; CDR: Clinical 
Dementia Rating Scale global score; LogMem: Logical memory subtest (I or II) of the Wechsler Memory Scale.
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Total Tau 2.0 kit (Quanterix, Lexington, USA) following the instructions of the kit manual. All samples were 
measured in a final 1:4 dilution.
CSF AD biomarker assessment. AD biomarkers were determined using commercially available kits 
according to vendor specifications (V-PLEX Aβ Peptide Panel 1 (6E10) Kit, K15200E and V-PLEX Human Total 
Tau Kit, K151LAE (Mesoscale Diagnostics LLC, Rockville, USA), and Innotest Phospho Tau(181P), 81581, 
Fujirebio Germany GmbH, Hannover, Germany).
Data analysis. All statistical analyses were carried out using the statistical analysis software package SPSS 
(version 24). The data are presented as mean ± standard deviation (SD). Significance for the results was set at 
P < 0.05. Continuous variables were tested for normal distribution with the Kolmogorov-Smirnov test. Levene’s 
test served to assess homogeneity of variances. We used the Pearson chi-square test to detect group differences 
in gender distribution and the nonparametric Mann-Whitney U-test to detect group differences in CDR scores. 
Group differences in age and education were assessed using one-way ANOVA.
Differences between HCs and SCD in global cognition (MMSE), LogMem I and II, as well as Aβ42, Aβ42/40 
ratio, CSF tau/Abeta42 ratio, tau and p-tau181 (if available), and plasma tau levels were assessed using one-way 
analyses of covariance (ANCOVA) controlling for age, gender, and education. Differences in tau plasma levels 
between normal HC and abnormal SCD according to different Aβ42 cut-off values (i.e. <600 pg/ml; on the basis 
of the Formula of Hulstaert16) and an Aβ42/40 ratio (i.e. <0.09) were evaluated using using one-way ANCOVA 
controlling for age, gender, and education.
Linear regression analysis were run to determine the relationship between tau plasma levels and age as well 
as with biochemical biomarkers (CSF levels of Aβ42, tau and p-tau181) or psychometric parameters (MMSE, 
LogMem I and II) controlling for age, gender, and education.
Results
Patients with SCD and HCs. Patients with SCD revealed significantly higher age compared to HCs 
(F[1,244] = 17.450; p < 0.001). CDR global score was significantly lower in HCs compared to SCD patients 
(p < 0.001). Gender (p = 0.374) and years of education (F[1,244] = 0.571; p < 0.450) were comparable between 
both groups. Additionally, MMSE (F[1,240] = 1.146; p < 0.285) scores as well as LogMem I (F[1,240] = 0.002; 
p < 0.960) and LogMem II (F[1,240] = 0.299; p < 0.585) subtest performance of the Wechsler Memory Scale did 
not differ between HCs and patients with SCD after controlling for age, gender, and education.
We found no significant different tau plasma levels (F[1,240] = 2.227; p = 0.137) in patients with SCD 
(3.4 pg/ml) compared with healthy controls (3.6 pg/ml) after controlling for age, gender, and education (Fig. 1). 
Additionally, tau plasma levels in SCD did not correlate with LogMem I (β = −0.084; 95% CI −0.774 to 0.262, 
p = 0.329) or LogMem II (β = −0.008; 95% CI −0.511 to 0.559, p = 0.929). However, there was a trend towards 
a negative association between tau plasma levels and MMSE (β = −0.176; 95% CI −0.276 to 0.001; p = 0.054).
All demographic, clinical, and neuropsychological parameters as well as tau plasma levels are displayed in 
Table 1.
Study participants with available CSF. Participants with available CSF differed significantly in age 
(F[1,93] = 10.501; p = 0.002) with lower mean age in HC individuals compared to patients with SCD. Gender 
was equally distributed between the investigated groups (p = 0.488). Years of education (p = 0.786) and 
MMSE (F[1,89] = 1.963; p = 0.165) did not differ significantly between the groups. Scores in the LogMem I 
(F[1,89] = 0.119; p = 0.731) or LogMem II (F[1,89] = 0.440; p = 0.167) subtest of the Wechsler Memory Scale did 
not differ between HCs and patients with SCD.
Figure 1. Plasma tau in HC individuals and SCD patients.
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After controlling for age, gender, and education we found no significant different tau plasma levels 
(F[1,89] = 0.238; p = 0.627) in patients with SCD (3.4 pg/ml) compared with HCs (3.6 pg/ml). Additionally, CSF 
levels of Aβ42 (F[1,89] = 3.327; p = 0.072), CSF Aβ42/40 ratio (F[1,89] = 0.095; p = 0.785), CSF tau/Abeta42 ratio 
(F[1,89] = 0.939; p = 0.335), tau (F[1,89] = 0.560; p = 0.456) and p-tau181 (F[1,89] = 0.320; p = 0.573) did not 
differ between the groups.
All demographic, clinical, and neuropsychological parameters as well as tau plasma, and CSF levels of Aβ42, 
tau, and p-tau181 for HC and SCD with available CSF are displayed in Table 2. Tau plasma levels in all SCD par-
ticipants with available CSF did not correlate with CSF levels of Aβ42 (β = 0; 95% CI −0.001 to 0.001, p = 0.663), 
tau (β = 0.001; 95% CI −0.004 to 0.001, p = 0.298), and p-tau181 (β = 0.011; 95% CI −0.027 to 0.005, p = 0.171) 
after controlling for age, gender, and education.
Subgroup analysis of HC individuals with normal Aβ42 levels (i.e. ≥600 pg/ml; n = 41) and SCD patients 
with abnormal Aβ42 levels (i.e. <600 pg/ml; n = 17) revealed no significant different tau plasma levels between 
both groups (HCs: 3.45 pg/ml vs. SCD: 3.29 pg/ml; p = 0.654). In abnormal SCD participants there were no sig-
nificant correlations between tau plasma levels and CSF levels of Aβ42 (r = −0.082; p = 0.782), tau (r = −0.413; 
p = 0.142), and p-tau181 (r = −0.226; p = 0.436) after controlling for age, gender, and education.
According to the Formula of Hulstaert16 no significant differences in tau plasma levels could be detected 
between normal HC individuals (3.47 pg/ml; n = 43) and SCD patients (3.31 pg/ml; n = 16; p = 0.642; Table 3). 
Tau plasma levels in abnormal SCD participants did not correlate with CSF levels of Aβ42 (β = 0.001; 95% CI 
−0.007 to 0.004, p = 0.527), tau (β = 0.003; 95% CI −0.006 to −0.001, p = 0.393), and p-tau181 (β = 0.019; 95% 
CI −0.038 to −0.001, p = 0.343) after controlling for age, gender, and education.
By using the Aβ42/40 quotient no significant differences in tau plasma levels between normal HC (i.e. 
Aβ42/40 ≥ 0.09 ratio; 3.49 pg/ml; n = 36) and abnormal SCD (i.e. Aβ42/40 < 0.09 ratio; 3.19 pg/ml; n = 17) could 
be detected (p = 0.366; Table 3). There were no significant associations between tau plasma levels and CSF levels 
of Aβ42 (β = 0.002; 95% CI −0.005 to 0.002, p = 0.316), tau (β = 0.003; 95% CI −0.005 to 0.000, p = 0.268), and 
p-tau181 (β = 0.014; 95% CI −0.032 to 0.005, p = 0.129) after controlling for age, gender, and education in abnor-
mal SCD (results not shown).
HC SMC p-value
N 50 45
Age (y) 68.0 (5.0) 71.3 (4.8) 0.002
Gender (m/f) 28/22 22/23 0.488
Education (y) 14.7 (2.8) 14.9 (3.4) 0.786
MMSE 29.5 (0.8) 29.2 (0.9) 0.165
CDR 0.0 (0.1) 0.2 (0.3) <0.001
LogMem I 15.5 (3.6) 14.9 (3.4) 0.731
LogMem II 14.9 (3.9) 13.8 (3.3) 0.509
Plasma tau 3.6 (1.3) 3.4 (1.2) 0.627
CSF Aβ42 890.0 (322.9) 747.7 (329.3) 0.072
CSF Aβ42/40 
ratio 0.098 (0.02) 0.093 (0.03) 0.758
CSF tau 359.0 (158.9) 365.6 (156.6) 0.456
CSF tau/Aβ42 
ratio 0.452 (0.3) 0.59 (0.4) 0.335
CSF p-tau181 51.2 (19.9) 50.9 (23.6) 0.573
Table 2. Clinical and demographic characteristics of HC individuals and SCD patients with available CSF levels 
of Aβ42, Ab42/40 ratio, tau, p-tau181, and CSF tau/Aβ42 ratio. Note: Values are expressed as mean (standard 
deviation). N: number; HC: healthy control individuals; SCD: patients with subjective cognitive decline; m/f: 
male/female; MMSE: Mini Mental State Examination; CDR: Clinical Dementia Rating Scale global score; 






Hulstaert-formula (Aβ42/tau ratio; cut-off <1) no. 43 16
Plasma tau 3.47 (1.1) 3.31 (1.3) 0.646
CSF Aβ42 (cut-off <600 pg/ml) no. 43 17
Plasma tau 3.45 (1.3) 3.29 (1.1) 0.654
CSF Aβ42/40 (cut-off <0.09) no. 36 17
Plasma tau 3.49 (1.2) 3.19 (0.9) 0.366
Table 3. Plasma tau levels of CSF negative (i.e. above cut-off) healthy controls (normal HC) and CSF positive 
(i.e. below cut-off) SCD patients (abnormal SCD) according to different cut-off levels using Aβ42, tau, and 
p-tau181. Note: Values are expressed as mean (standard deviation) or number (no.) above /below cut-off.
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Discussion
As main finding of the present study, SCD patients showed no significantly different tau plasma levels in compar-
ison with cognitively healthy controls in the whole study cohort and in the subgroup with available CSF. Given 
that SCD patients did also not show significantly different tau and p-tau181 CSF levels compared with healthy 
controls in the subgroup with available CSF, this finding was not surprising. However, even if different cut-off 
values of CSF Aβ42 and ratios with tau and Aβ40 were used to classify HCs with normal CSF values (i.e. Aβ42 
above cut-off) and SCD patients with abnormal CSF values (i.e. Aβ42 below cut-off), tau plasma levels did not 
differ between these groups. Our results validate and extend the findings of the recently published BioFINDER 
(Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably) study at Lund University, Sweden, 
examining tau plasma levels in 174 SCD patients and 274 healthy controls5. This study also failed to demon-
strate increased tau plasma levels in SCD patients. Although negative, this consistent result of two independent 
European studies is important as it indicates that tau plasma levels are not a useful diagnostic measure for the 
pre-MCI stage of SCD. It is noteworthy that plasma tau peptides did not correlate with CSF tau peptides in SCD 
patients. This lack of correlation between tau levels in plasma and CSF is in line with the findings of previous 
studies5, 6. This suggests that tau levels are affected by different factors in both biofluids. Tau may derive from 
different sources in both body fluids, or the analysis in plasma might be influenced by unknown factors at lower 
levels, since a correlation has been reported for higher levels5.
Although there was no increased tau or p-tau in the SCD group compared to HC individuals, a statistical 
trend towards lower Aß42 concentration in SCD patients compared to HCs was observable. This might suggest 
that earliest cognitive changes (i.e. SCD) may already occur in the stage of Aß42 accumulation in the absence of 
significant neurodegeneration19.
Previous studies showed increased tau plasma levels in patients with AD4–6, in a group of patients with AD 
and mild cognitive impairment (MCI) due to AD7 and in MCI due to AD4, but not in clinically classified MCI 
groups converting or not to AD during follow-up5, 6. Taken together, our own result and these findings in litera-
ture indicate that plasma tau is a late marker of neurodegeneration, requiring substantial injury before increasing 
to abnormal levels at the transition from MCI to dementia stage of AD.
As limitation of the study, CSF was not available in all study participants but only in a subgroup of 45 SCD 
patients and 49 healthy controls. In addition, currently no follow-up data were available. Additionally, the 
Formular of Hulstaert and cut-off levels of Abeta and tau are not widely accepted standards for peripheral bio-
marker analysis. Positive outcomes would reinforce the values of the formula and cut-off levels, but negative 
outcomes are not informative.
In conclusion, plasma tau is not altered in the examined cohort of subjects at increased risk for AD. In addi-
tion, the lack of correlation between tau in plasma and CSF in the examined cohort suggests that tau levels are 
affected by different factors in both biofluids.
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